Pharma Mar Company Profile (NASDAQ:PHMMF)

About Pharma Mar (NASDAQ:PHMMF)

Pharma Mar logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PHMMF
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $4.01
  • 200 Day Moving Avg: $4.19
  • 52 Week Range: $2.40 - $4.80
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $223.8 million
  • Price / Sales: N/A
  • Book Value: $0.29 per share
  • Price / Book: 12.94
Profitability:
  • EBITDA: ($12,890,000.00)
Misc:
  • Average Volume: 10,087 shs.
 

Frequently Asked Questions for Pharma Mar (NASDAQ:PHMMF)

What is Pharma Mar's stock symbol?

Pharma Mar trades on the NASDAQ under the ticker symbol "PHMMF."

Who are some of Pharma Mar's key competitors?

How do I buy Pharma Mar stock?

Shares of Pharma Mar can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharma Mar's stock price today?

One share of Pharma Mar stock can currently be purchased for approximately $3.69.


MarketBeat Community Rating for Pharma Mar (NASDAQ PHMMF)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  95
MarketBeat's community ratings are surveys of what our community members think about Pharma Mar and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pharma Mar (NASDAQ:PHMMF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Pharma Mar (NASDAQ:PHMMF)
Price Target History for Pharma Mar (NASDAQ:PHMMF)
Analysts' Ratings History for Pharma Mar (NASDAQ:PHMMF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Pharma Mar (NASDAQ:PHMMF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Pharma Mar (NASDAQ:PHMMF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Pharma Mar (NASDAQ:PHMMF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pharma Mar (NASDAQ:PHMMF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Pharma Mar (NASDAQ:PHMMF)
Latest Headlines for Pharma Mar (NASDAQ:PHMMF)
Source:
DateHeadline
finance.yahoo.com logoThe World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL1001
finance.yahoo.com - October 20 at 7:32 AM
finance.yahoo.com logoFinal Data on Phase I/II in Small-cell Lung Cancer with Zepsyre® Presented at the IASCLC 18th World Conference on Lung Cancer in Japan
finance.yahoo.com - October 19 at 7:30 AM
finance.yahoo.com logoPharmaMar Will Present Final Data on PM1183 During the 18th World Lung Conference in Japan
finance.yahoo.com - October 11 at 6:33 AM
finance.yahoo.com logoPharmaMar: Sylentis Presents New Data on a New Eye Drop siRNA for the Treatment of Retinal Diseases Avoiding Intraocular Injections
finance.yahoo.com - September 25 at 11:32 AM
finance.yahoo.com logoPharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors
finance.yahoo.com - September 20 at 7:44 AM
finance.yahoo.com logoPharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors
finance.yahoo.com - September 20 at 7:44 AM
finance.yahoo.com logoNew Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer
finance.yahoo.com - September 12 at 8:35 AM
finance.yahoo.com logoPharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017
finance.yahoo.com - September 1 at 7:13 AM
americanbankingnews.com logo Pharma Mar (NASDAQ:PHMMF) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - August 15 at 12:28 AM
finance.yahoo.com logoPharmaMar Starts a Quadruple Combination Study With Aplidin® for the Treatment of Multiple Myeloma
finance.yahoo.com - August 10 at 6:49 AM
seekingalpha.com logoTalking With PharmaMar's Management About Its Upcoming Pivotal Year
seekingalpha.com - March 16 at 7:56 PM

Social

Chart

Pharma Mar (PHMMF) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.